Study flags need to monitor frailty risks with GLP-1 drugs for older adults

Key Points:

• A large study highlights potential frailty concerns in older adults using Eli Lilly's obesity drug Zepbound (tirzepatide), suggesting higher risks of adverse outcomes like malnutrition, dehydration, and muscle loss, especially with significant weight loss.
• Despite these risks, researchers emphasize that frailty-associated conditions are rare and should not discourage the appropriate use of Zepbound or Novo Nordisk's Wegovy (semaglutide) in seniors, but recommend closer monitoring of older patients.
• The study found that older patients on tirzepatide who developed frailty conditions had significantly higher risks of death, hospitalization, and ICU admission compared to those on other diabetes treatments or weight-loss surgery.
• Frailty symptoms typically appeared after six months of treatment, indicating the importance of ongoing follow-up and early intervention, including potentially stopping the drug if signs of frailty emerge.
• Experts note the need for further research to confirm these findings and explore preventive measures like resistance exercise and protein supplementation, while advising clinicians to remain vigilant but not alarmed given the benefits of GLP-1 therapies.